ZIVOCorporate Update•businesswire•
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
Sentiment:Positive (68)
Summary
(ZIVO) TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direc
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 10, 2025 by businesswire